Cargando…

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Modern therapy of advanced melanoma offers effective targeted therapeutic options in the form of BRAF plus MEK inhibition for patients with BRAF V600 mutations. For patients lacking these mutations, checkpoint inhibition remains the only first-line choice for treatment of metastatic disease. However...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menzer, Christian, Hassel, Jessica C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Skin Cancer (T Ito, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042969/ https://www.ncbi.nlm.nih.gov/pubmed/35380338 http://dx.doi.org/10.1007/s11864-022-00946-4

Ejemplares similares

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies
por: Zhong, Jingqin, et al.
Publicado: (2022)

Targeted Therapy and Immunotherapy for Melanoma in Japan
por: Namikawa, Kenjiro, et al.
Publicado: (2019)

Advanced Acral Melanoma Therapies: Current Status and Future Directions
por: Zhang, Yiqun, et al.
Publicado: (2022)

Autophagy Paradox: Strategizing Treatment Modality in Melanoma
por: Pangilinan, Christian, et al.
Publicado: (2023)

Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma
por: Zelin, Enrico, et al.
Publicado: (2021)

Clinical Application of Artificial Intelligence for Non-melanoma Skin Cancer
por: Sanchez, Katherine, et al.
Publicado: (2023)

Localized Non-melanoma Skin Cancer: Risk Factors of Post-surgical Relapse and Role of Postoperative Radiotherapy
por: Caparrotti, Francesca, et al.
Publicado: (2020)

Dermatoscopy of Neoplastic Skin Lesions: Recent Advances, Updates, and Revisions
por: Weber, Philipp, et al.
Publicado: (2018)

BRAF(V600E) Expression Is Homogenous and Associated with Nonrecurrent Disease and Better Survival in Primary Melanoma
por: Naimy, Soraya, et al.
Publicado: (2023)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Congenital ichthyosis patient with squamous cell carcinoma of the skin who received concurrent chemoradiation: A case report
por: Cerra-Franco, Alberto, et al.
Publicado: (2017)

Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
por: Sigalotti, L, et al.
Publicado: (2011)

BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current Knowledge
por: Florent, Laetitia, et al.
Publicado: (2023)

Development of encorafenib for BRAF-mutated advanced melanoma
por: Koelblinger, Peter, et al.
Publicado: (2018)

Onset of vitiligo following targeted therapy for BRAF(V600E)-mutated melanoma: case report
por: Brugnara, Sonia, et al.
Publicado: (2019)

Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets
por: Improta, Giuseppina, et al.
Publicado: (2013)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
por: Moser, Justin C., et al.
Publicado: (2019)

Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation
por: Kocovski, Linda, et al.
Publicado: (2015)

BRAF V600 mutations and pathological features in Japanese melanoma patients
por: Yamazaki, Naoya, et al.
Publicado: (2015)

Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot
por: Iwama, Eimei, et al.
Publicado: (2015)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

BRAF(V600E )mutations in malignant melanoma are associated with increased expressions of BAALC
por: Schrama, David, et al.
Publicado: (2008)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
por: Fisher, Rosalie, et al.
Publicado: (2012)

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma
por: Zepeda-Lopez, Priscilla Denise, et al.
Publicado: (2016)

Insight on BRAF(V600E) mutated colorectal cancer immune microenvironment
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma
por: Ruiz-Garcia, Erika, et al.
Publicado: (2017)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF(V600) melanoma
por: Smith, Lorey K., et al.
Publicado: (2022)

Can ultraviolet radiation act as a survival enhancer for cutaneous melanoma?
por: Fortes, Cristina, et al.
Publicado: (2016)

Analysis of Geographic and Environmental Factors and Their Association with Cutaneous Melanoma Incidence in Canada
por: Berman-Rosa, Melissa, et al.
Publicado: (2022)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

BRAF(V600E) cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis
por: Sakamoto, Naoya, et al.
Publicado: (2017)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

BRAF V600E mutational load as a prognosis biomarker in malignant melanoma
por: Sevilla, Arrate, et al.
Publicado: (2020)

Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma
por: Meckbach, Diana, et al.
Publicado: (2014)

PO-0267 Contact Skin Radiotherapy for advanced non melanoma skin cancer during COVID-19 pandemic.
por: Lancellotta, V.
Publicado: (2021)

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting
por: Gibney, Geoffrey T, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_djrclo4j5u4s3sek0phbtde67i